Thieblemont, C., Tchernonog, E., Munir, T., Miles, O., Schwaner, I., Consoli, U., Innao, V., Mele, A., Farias, D. D., Scheliga, A., Kay, N., Absi, A., Stemer, G., Tadmor, T., Hoffman, M., Koffman, B., Messahel, B., Srikanthan, S., Franceschini, E., Abbazio, C., Xu, P., Tapprich, C., Kavanagh, C., Fouad, M., Parisi, L., Wildgust, M., Ghia, P. (2025). Real-world (RW) use of fixed-duration (FD) ibrutinib+venetoclax (Ibr+Ven) in patients (pts) with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Pooled analysis of REALITY-worldwide (WW) and REALITY-2 prospective cohort studies. Blood. https://doi.org/10.1182/blood-2025-3903